Report cover image

Beef Cattle Health Market Size, Share & Trends Analysis Report By Product (Biologics, Pharmaceuticals, Medicated Feed Additives), By Distribution Channel (Retail, E-commerce, Hospital/Clinic Pharmacy), By Region, And Segment Forecasts, 2025 - 2033

Publisher Grand View Research
Published Oct 28, 2025
Length 150 Pages
SKU # GV20575183

Description

Beef Cattle Health Market Summary

The global beef cattle health market size was estimated at USD 5.85 billion in 2024 and is projected to reach USD 12.22 billion by 2033, growing at a CAGR of 8.80% from 2025 to 2033. The market is experiencing growth driven by the rising prevalence of infectious and parasitic diseases, such as bovine respiratory disease and New World screwworm, which threaten herd productivity.

Innovations like injectable antibiotics and parasitic treatments, along with increased adoption of preventive healthcare and medicated feed additives, are boosting demand for effective cattle health solutions worldwide. Additionally, expanding awareness among producers about disease management, animal welfare, and productivity optimization has led to higher consumption of pharmaceuticals, biologics, and medicated feed additives. For example, rising concerns over bovine respiratory disease and foot-and-mouth disease have fueled the demand for vaccines and antibiotics, while nutritional supplements and probiotics are increasingly used to enhance feed efficiency and immunity.

According to the report published by Ceva in July 2025, global beef prices will remain strong in June 2025, driven by tight cattle supplies and robust demand. In Europe and the USA, prices surged over 40% year-on-year, while Brazil saw steady growth supported by booming exports. China's prices stabilized after earlier gains, as increased imports balanced the market. Overall, global demand for beef continues to outpace supply. High cattle prices and strong international demand encourage producers to invest more in herd health, disease prevention, and productivity enhancement. This trend will likely boost the beef cattle health market, driving growth in vaccines, feed additives, and veterinary services to sustain herd performance and export quality.

Additionally, the increasing prevalence of infectious and parasitic diseases and growing FDA approvals for innovative products to maintain beef cattle health are expected to drive market growth. For instance, in September 2025, the FDA approved Dectomax-CA1 for New World screwworm prevention and treatment, highlighting the urgent need for effective parasitic control in cattle. Similarly, in February 2025, Elanco’s launch of Pradalex, a novel injectable antibiotic for bovine respiratory disease (BRD), underscores the demand for advanced therapeutics to manage highly prevalent and costly respiratory infections in feedlot and stocker cattle. These innovations enhance herd health, reduce mortality, and improve overall production efficiency, encouraging greater adoption of veterinary pharmaceuticals and biologics globally.

Market Concentration & Characteristics

The global beef cattle health market is moderately concentrated, with a few major players controlling a significant share of pharmaceuticals, biologics, and feed additive segments. These key players focus on expanding regional footprints, product portfolios, and R&D capabilities, driving innovation and market stability. Smaller regional companies also contribute by catering to niche markets and local regulatory requirements, maintaining competitive dynamics.

The global beef cattle health industry is experiencing strong innovation, driven by advanced biologics, precision pharmaceuticals, and novel feed additives. Key developments include mRNA vaccines for viral diseases, CRISPR-based microbiome editing to reduce methane emissions, and probiotics or enzyme-based supplements to enhance feed efficiency and gut health. Innovative delivery systems, such as intranasal vaccines and sustained-release formulations, improve disease prevention and herd health management. These advances are boosting productivity, sustainability, and overall cattle well-being worldwide.

Global Beef Cattle Health Market Report Segmentation

This report forecasts revenue growth at the global, regional & country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global beef cattle health market report based on product, distribution channel, and region:
  • Product Outlook (Revenue, USD Million, 2021 - 2033)
  • Biologics
  • Vaccines
  • Attenuated Live Vaccines
  • Inactivated Vaccines
  • Subunit Vaccines
  • DNA Vaccines
  • Recombinant Vaccines
  • Autogenous Vaccines
  • Other Biologics
  • Pharmaceuticals
  • Parasiticides
  • Anti-infectives
  • Anti-inflammatory
  • Analgesics
  • Others
  • Medicated Feed Additives
  • Distribution Channel Outlook (Revenue, USD Million, 2021 - 2033)
  • Retail
  • E-commerce
  • Hospital/Clinic Pharmacy
  • Regional Outlook (Revenue, USD Million, 2021 - 2033)
  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Russia
  • Netherlands
  • Switzerland
  • Ireland
  • Poland
  • Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
  • Indonesia
  • Philippines
  • Malaysia
  • Singapore
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman
  • Turkey
  • Iran
  • Israel
  • Egypt
Please note The report will be delivered in 2-3 business days upon order notification.

Table of Contents

150 Pages
Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Distribution Channel
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased Database
1.4.2. GVR’s Internal Database
1.4.3. Secondary Sources
1.4.4. Primary Research
1.5. Information/Data Analysis
1.5.1. Data Analysis Models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Model 1 Analysis
1.7.2. Model 2 Analysis
1.7.3. Model 3 Analysis
1.8. List of Secondary Sources
1.9. List of Abbreviations
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Market Variable Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Ancillary/Related Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Growing beef availability for domestic consumption
3.2.1.2. Strong international demand for beef
3.2.1.3. Supportive initiatives
3.2.2. Market Restraint Analysis
3.2.2.1. Regulatory challenges
3.2.2.2. Adverse environmental conditions
3.2.3. Market Opportunity Analysis
3.2.4. Market Challenge Analysis
3.3. Pricing Analysis
3.4. Estimated Animal Population, 2024
3.5. Market Analysis Tools
3.5.1. Porter’s Five Forces Analysis
3.5.2. PESTEL by SWOT Analysis
Chapter 4. Global Beef Cattle Health Market: Product Estimates & Trend Analysis
4.1. Global Beef Cattle Health Market, By Product: Segment Dashboard
4.2. Global Beef Cattle Health Market, By Product Movement Analysis
4.3. Global Beef Cattle Health Market Estimates & Forecasts, by Product, 2021 to 2033 (USD Million)
4.4. Biologics
4.4.1. Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.1.1. Vaccines
4.4.1.1.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.1.1.2. Attenuated Live Vaccines
4.4.1.1.2.1. Attenuated Live Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.1.1.3. Inactivated Vaccines
4.4.1.1.3.1. Inactivated Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.1.1.4. Subunit Vaccines
4.4.1.1.4.1. Subunit Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.1.1.5. DNA Vaccines
4.4.1.1.5.1. DNA Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.1.1.6. Recombinant Vaccines
4.4.1.1.6.1. Recombinant Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.1.1.7. Autogenous Vaccines
4.4.1.1.7.1. Autogenous Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.4.1.2. Other Biologics
4.4.1.2.1. Other Biologics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5. Pharmaceuticals
4.5.1. Pharmaceuticals Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.1.1. Parasiticides
4.5.1.1.1. Parasiticides Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.1.2. Anti-infectives
4.5.1.2.1. Anti-infectives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.1.3. Anti-inflammatory
4.5.1.3.1. Anti-inflammatory Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.1.4. Analgesics
4.5.1.4.1. Analgesics Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.5.1.5. Others
4.5.1.5.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)
4.6. Medicated Feed Additives
4.6.1. Medicated Feed Additives Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 5. Global Beef Cattle Health Market: By Distribution Channel Estimates & Trend Analysis
5.1. Global Beef Cattle Health Market, By Distribution Channel: Segment Dashboard
5.2. Global Beef Cattle Health Market, By Distribution Channel Movement Analysis
5.3. Global Beef Cattle Health Market Estimates & Forecasts, by Distribution Channel, 2021 to 2033 (USD Million)
5.4. Hospital/Clinic Pharmacy
5.4.1. Hospital/Clinic Pharmacy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.5. Retail
5.5.1. Retail Market Estimates and Forecasts, 2021 - 2033 (USD Million)
5.6. E-commerce
5.6.1. E-commerce Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 6. Global Beef Cattle Health Market: By Regional Estimates & Trend Analysis
6.1. Region Market Dashboard
6.2. Region Market Share Analysis, 2024 & 2033
6.3. North America
6.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.2. U.S
6.3.2.1. Key Country Dynamics
6.3.2.2. Competitive Scenario
6.3.2.3. Regulatory Framework
6.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.3. Canada
6.3.3.1. Key Country Dynamics
6.3.3.2. Competitive Scenario
6.3.3.3. Regulatory Framework
6.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.3.4. Mexico
6.3.4.1. Key Country Dynamics
6.3.4.2. Competitive Scenario
6.3.4.3. Regulatory Framework
6.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4. Europe
6.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.2. UK
6.4.2.1. Key Country Dynamics
6.4.2.2. Competitive Scenario
6.4.2.3. Regulatory Framework
6.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.3. Germany
6.4.3.1. Key Country Dynamics
6.4.3.2. Competitive Scenario
6.4.3.3. Regulatory Framework
6.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.4. France
6.4.4.1. Key Country Dynamics
6.4.4.2. Competitive Scenario
6.4.4.3. Regulatory Framework
6.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.5. Italy
6.4.5.1. Key Country Dynamics
6.4.5.2. Competitive Scenario
6.4.5.3. Regulatory Framework
6.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.6. Spain
6.4.6.1. Key Country Dynamics
6.4.6.2. Competitive Scenario
6.4.6.3. Regulatory Framework
6.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.7. Russia
6.4.7.1. Key Country Dynamics
6.4.7.2. Competitive Scenario
6.4.7.3. Regulatory Framework
6.4.7.4. Russia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.8. Netherlands
6.4.8.1. Key Country Dynamics
6.4.8.2. Competitive Scenario
6.4.8.3. Regulatory Framework
6.4.8.4. Netherlands Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.9. Switzerland
6.4.9.1. Key Country Dynamics
6.4.9.2. Competitive Scenario
6.4.9.3. Regulatory Framework
6.4.9.4. Switzerland Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.10. Sweden
6.4.10.1. Key Country Dynamics
6.4.10.2. Competitive Scenario
6.4.10.3. Regulatory Framework
6.4.10.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.11. Ireland
6.4.11.1. Key Country Dynamics
6.4.11.2. Competitive Scenario
6.4.11.3. Regulatory Framework
6.4.11.4. Ireland Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.12. Poland
6.4.12.1. Key Country Dynamics
6.4.12.2. Competitive Scenario
6.4.12.3. Regulatory Framework
6.4.12.4. Poland Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.13. Denmark
6.4.13.1. Key Country Dynamics
6.4.13.2. Competitive Scenario
6.4.13.3. Regulatory Framework
6.4.13.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.4.14. Norway
6.4.14.1. Key Country Dynamics
6.4.14.2. Competitive Scenario
6.4.14.3. Regulatory Framework
6.4.14.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5. Asia Pacific
6.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.2. Japan
6.5.2.1. Key Country Dynamics
6.5.2.2. Competitive Scenario
6.5.2.3. Regulatory Framework
6.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.3. China
6.5.3.1. Key Country Dynamics
6.5.3.2. Competitive Scenario
6.5.3.3. Regulatory Framework
6.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.4. India
6.5.4.1. Key Country Dynamics
6.5.4.2. Competitive Scenario
6.5.4.3. Regulatory Framework
6.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.5. Indonesia
6.5.5.1. Key Country Dynamics
6.5.5.2. Competitive Scenario
6.5.5.3. Regulatory Framework
6.5.5.4. Indonesia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.6. Thailand
6.5.6.1. Key Country Dynamics
6.5.6.2. Competitive Scenario
6.5.6.3. Regulatory Framework
6.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.7. South Korea
6.5.7.1. Key Country Dynamics
6.5.7.2. Competitive Scenario
6.5.7.3. Regulatory Framework
6.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.8. Australia
6.5.8.1. Key Country Dynamics
6.5.8.2. Competitive Scenario
6.5.8.3. Regulatory Framework
6.5.8.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.9. Philippines
6.5.9.1. Key Country Dynamics
6.5.9.2. Competitive Scenario
6.5.9.3. Regulatory Framework
6.5.9.4. Philippines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.10. Malaysia
6.5.10.1. Key Country Dynamics
6.5.10.2. Competitive Scenario
6.5.10.3. Regulatory Framework
6.5.10.4. Malaysia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.5.11. Singapore
6.5.11.1. Key Country Dynamics
6.5.11.2. Competitive Scenario
6.5.11.3. Regulatory Framework
6.5.11.4. Singapore Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6. Latin America
6.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.2. Brazil
6.6.2.1. Key Country Dynamics
6.6.2.2. Competitive Scenario
6.6.2.3. Regulatory Framework
6.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.6.3. Argentina
6.6.3.1. Key Country Dynamics
6.6.3.2. Competitive Scenario
6.6.3.3. Regulatory Framework
6.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7. MEA
6.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.2. South Africa
6.7.2.1. Key Country Dynamics
6.7.2.2. Competitive Scenario
6.7.2.3. Regulatory Framework
6.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.3. Saudi Arabia
6.7.3.1. Key Country Dynamics
6.7.3.2. Competitive Scenario
6.7.3.3. Regulatory Framework
6.7.3.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.4. Turkey
6.7.4.1. Key Country Dynamics
6.7.4.2. Competitive Scenario
6.7.4.3. Regulatory Framework
6.7.4.4. Turkey Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.5. Iran
6.7.5.1. Key Country Dynamics
6.7.5.2. Competitive Scenario
6.7.5.3. Regulatory Framework
6.7.5.4. Iran Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.6. UAE
6.7.6.1. Key Country Dynamics
6.7.6.2. Competitive Scenario
6.7.6.3. Regulatory Framework
6.7.6.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.7. Israel
6.7.7.1. Key Country Dynamics
6.7.7.2. Competitive Scenario
6.7.7.3. Regulatory Framework
6.7.7.4. Israel Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.8. Kuwait
6.7.8.1. Key Country Dynamics
6.7.8.2. Competitive Scenario
6.7.8.3. Regulatory Framework
6.7.8.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.9. Egypt
6.7.9.1. Key Country Dynamics
6.7.9.2. Competitive Scenario
6.7.9.3. Regulatory Framework
6.7.9.4. Egypt Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.10. Qatar
6.7.10.1. Key Country Dynamics
6.7.10.2. Competitive Scenario
6.7.10.3. Regulatory Framework
6.7.10.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
6.7.11. Oman
6.7.11.1. Key Country Dynamics
6.7.11.2. Competitive Scenario
6.7.11.3. Regulatory Framework
6.7.11.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)
Chapter 7. Competitive Landscape
7.1. Market Participant Categorization
7.1.1. Market Leaders
7.1.2. Emerging Players
7.2. Market Share/Assessment Analysis, 2024 (Heat Map Analysis)
7.3. Company Profiles
7.3.1. Zoetis Inc.
7.3.1.1. Participant’s Overview
7.3.1.2. Financial Performance
7.3.1.3. Product/Service Benchmarking
7.3.1.4. Strategic Initiatives
7.3.2. Boehringer Ingelheim International GmbH
7.3.2.1. Participant’s Overview
7.3.2.2. Financial Performance
7.3.2.3. Product/Service Benchmarking
7.3.2.4. Strategic Initiatives
7.3.3. Merck & Co., Inc.
7.3.3.1. Participant’s Overview
7.3.3.2. Financial Performance
7.3.3.3. Product/Service Benchmarking
7.3.3.4. Strategic Initiatives
7.3.4. Virbac
7.3.4.1. Participant’s Overview
7.3.4.2. Financial Performance
7.3.4.3. Product/Service Benchmarking
7.3.4.4. Strategic Initiatives
7.3.5. Elanco
7.3.5.1. Participant’s Overview
7.3.5.2. Financial Performance
7.3.5.3. Product/Service Benchmarking
7.3.5.4. Strategic Initiatives
7.3.6. Vetoquinol S.A
7.3.6.1. Participant’s Overview
7.3.6.2. Financial Performance
7.3.6.3. Product/Service Benchmarking
7.3.6.4. Strategic Initiatives
7.3.7. Phibro Animal Health Corporation
7.3.7.1. Participant’s Overview
7.3.7.2. Financial Performance
7.3.7.3. Product/Service Benchmarking
7.3.7.4. Strategic Initiatives
7.3.8. Norbrook
7.3.8.1. Participant’s Overview
7.3.8.2. Financial Performance
7.3.8.3. Product/Service Benchmarking
7.3.8.4. Strategic Initiatives
7.3.9. Dechra Pharmaceuticals Plc
7.3.9.1. Participant’s Overview
7.3.9.2. Financial Performance
7.3.9.3. Product/Service Benchmarking
7.3.9.4. Strategic Initiatives
7.3.10. Bimeda, Inc
7.3.10.1. Participant’s Overview
7.3.10.2. Financial Performance
7.3.10.3. Product/Service Benchmarking
7.3.10.4. Strategic Initiatives
7.3.11. Cargill, Incorporated
7.3.11.1. Participant’s Overview
7.3.11.2. Financial Performance
7.3.11.3. Product/Service Benchmarking
7.3.11.4. Strategic Initiatives
7.4. List of other key players

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us